Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Visioli Christopher

2. Date of Event Requiring Statement (MM/DD/YYYY) 3/21/2018

3. Issuer Name and Ticker or Trading Symbol

MEDICINES CO /DE [MDCO]

(Last) (First) (Middle)

C/O THE MEDICINES COMPANY, 8 SYLVAN WAY

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___ X ___ Officer (give title below) _____ Other (specify below)
Chief Financial Officer /

(Street)

PARSIPPANY, NJ 07054

(City) (State) (Zip)

5. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	8161	D

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right-to-buy)	⁽¹⁾	2/18/2021	Common Stock	6000	$17.45	D
Stock Option (right-to-buy)	⁽²⁾	2/24/2022	Common Stock	6635	$22.04	D
Stock Option (right-to-buy)	⁽³⁾	3/1/2023	Common Stock	1441	$31.49	D
Stock Option (right-to-buy)	⁽⁴⁾	3/1/2024	Common Stock	3477	$30.55	D
Stock Option (right-to-buy)	⁽⁵⁾	3/1/2025	Common Stock	4375	$28.77	D
Stock Option (right-to-buy)	⁽⁶⁾	3/1/2025	Common Stock	16500	$28.77	D
Stock Option (right-to-buy)	⁽⁷⁾	3/1/2026	Common Stock	12889	$33.04	D
Stock Option (right-to-buy)	⁽⁸⁾	3/1/2027	Common Stock	15810	$52.70	D

Explanation of Responses:
(1)	Remainder of a grant of 20,000 stock options made to the reporting person on February 18, 2011. The remaining option vested in forty-eight equal monthly installments beginning March 18, 2011.
(2)	Remainder of a grant of 12,500 stock options made to the reporting person on February 24, 2012. The remaining option vested in forty-eight equal monthly installments beginning March 24, 2012.
(3)	Remainder of a grant of 3,843 stock options made to the reporting person on March 1, 2013. The remaining option vested in forty-eight equal monthly installments beginning April 1, 2013.
(4)	Remainder of a grant of 7,163 stock options made to the reporting person on March 1, 2014. The remaining option vested in forty-eight equal monthly installments beginning April 1, 2014.
(5)	Remainder of a grant of 5,000 stock options made to the reporting person on March 1, 2015. The option vests in equal monthly installments ending on April 1, 2019.
(6)	Remainder of a grant of 20,000 stock options made to the reporting person on March 1, 2015. The option vests in equal monthly installments ending on April 1, 2019.
(7)	Remainder of a grant of 14,889 stock options made to the reporting person on March 1, 2016. The option vests in equal monthly installments ending on April 1, 2020.
(8)	Grant made to the reporting person on March 1, 2017. The option vests in forty-eight equal installments ending April 1, 2021.

Remarks:
Exhibit List: Exhibit 24.1 - Power of Attorney

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Visioli Christopher C/O THE MEDICINES COMPANY 8 SYLVAN WAY PARSIPPANY, NJ 07054			Chief Financial Officer

Signatures
/s/ Stephen M. Rodin, Attorney-in-Fact for Christopher Visioli		4/2/2018
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.